entertainment
A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.
Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.
advertisement
“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get StartedThen $39/month
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： Activists slam private health insurers over coverage restrictions
